Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 109 results for ovarian cancer

  1. Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]

    In development Reference number: GID-TA11774 Expected publication date:  30 September 2026

    Technology appraisal guidance
    In development

  2. The value of primary surgery for women with advanced ovarian cancer:- Research should be undertaken to determine the effectiveness of primary surgery for women with advanced ovarian cancer whose tumour cannot be fully excised.

    advanced ovarian cancer:- Research should be undertaken to determine the effectiveness of primary surgery for women with advanced...

    Research recommendation
    Published
    9 June 2015

  3. Imaging in the diagnostic pathway for women with ovarian cancer:- Large multicentre case–control studies should be conducted to compare the accuracy of CT versus MRI for staging and for predicting optimal cytoreduction in women with ovarian cancer.

    Question Imaging in the diagnostic pathway for women with ovarian cancer:- Large multicentre case–control studies should be conducted...

    Research recommendation
    Published
    9 June 2015

  4. Relationship between duration of symptoms of ovarian cancer and stage at diagnosis:- Further research should be undertaken on the relationship between the duration and frequency of symptoms in women with ovarian cancer before diagnosis, the stage of disease at diagnosis and subsequent survival.

    CG122/1 Question Relationship between duration of symptoms of ovarian cancer and stage at diagnosis:- Further research should be...

    Research recommendation
    Published
    9 June 2015

  5. Early and locally advanced breast cancer: diagnosis and management (NG101)

    This guideline covers diagnosing and managing early and locally advanced breast cancer. It aims to help healthcare professionals offer the right treatments to people, taking into account the person's individual preferences.

    NICE guideline
    Last updated
    14 April 2025
    View recommendations

    Sections for NG101

  6. Metastatic malignant disease of unknown primary origin in adults: diagnosis and management (CG104)

    This guideline covers diagnosing and managing secondary cancer in people aged 18 and over when the site of the primary cancer is unknown. This includes people who have had treatment for cancer before. It aims to improve quality of life by offering advice on tests for identifying the site of the primary cancer and options for managing the person’s condition.

    Clinical guideline
    Last updated
    26 April 2023
    View recommendations

    Sections for CG104

  7. Fertility problems (QS73)

    This quality standard covers assessing and treating fertility problems in people with explained and unexplained infertility, including access to IVF treatment. It also covers cryopreservation before cancer treatment that may affect fertility. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    23 October 2014
    View quality statements

    Sections for QS73

  8. Lurbinectedin for treating advanced platinum-resistant ovarian cancer [ID1340]

    In development Reference number: GID-TA10313 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Removal, preservation and reimplantation of ovarian tissue for restoring fertility after gonadotoxic treatment (HTG693)

    Evidence-based recommendations on removal, preservation and reimplantation of ovarian tissue for restoring fertility after gonadotoxic treatment. This involves surgically removing ovarian tissue before a treatment for cancer or other medical condition that can damage the ovaries (gonadotoxic treatment) begins. The ovarian tissue is then frozen to be reimplanted after the gonadotoxic treatment is finished, to restore fertility.

    HealthTech guidance
    Published
    21 September 2023
    View recommendations

    Sections for HTG693

  10. Removal, preservation and subsequent reimplantation of ovarian tissue to prevent symptoms from the menopause (HTG640)

    Evidence-based recommendations on removal, preservation and subsequent reimplantation of ovarian tissue to prevent symptoms from the menopause. This involves removing a small piece of ovarian tissue using keyhole surgery, freezing and storing it. After menopause starts, the tissue is thawed and transplanted under the skin of the armpit, abdomen or forearm, with the aim of producing oestrogen.

    HealthTech guidance
    Published
    21 September 2022
    View recommendations

    Sections for HTG640

  11. Chemoprevention to reduce incidence of breast cancer:- A randomised controlled trial is recommended to compare the clinical and cost effectiveness of aromatase inhibitors and tamoxifen for reducing the incidence of breast cancer in women with a family history of breast or ovarian cancer. [new 2013]

    CG164/4 Question Chemoprevention to reduce incidence of breast cancer:- A randomised controlled trial is recommended to compare the...

    Research recommendation
    Published
    9 June 2015

  12. Past appeals and decisions

    Past technology appraisal appeals and decisions

  13. Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]

    In development Reference number: GID-TA10446 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Ovarian cancer - vintafolide (with pegylated liposomal doxorubicin) [ID564]

    Discontinued Reference number: GID-TAG332

    Technology appraisal guidance
    Discontinued

  15. AT406 for neoadjuvant treatment of epithelial ovarian cancer [ID1428]

    Discontinued Reference number: GID-TA10809

    Technology appraisal guidance
    Discontinued